Literature DB >> 21670186

Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.

Chadi A Hage1, Patricia Connolly, Daniel Horan, Michelle Durkin, Melinda Smedema, Robert Zarnowski, Patricia Smith, L Joseph Wheat.   

Abstract

Micafungin alone and combined with liposomal amphotericin B was evaluated against two strains of Histoplasma capsulatum. Micafungin was active in vitro against the mold but not the yeast form but was ineffective in vivo. Micafungin appears to be ineffective in treatment of histoplasmosis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21670186      PMCID： PMC3165286          DOI： 10.1128/AAC.01681-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

2.  Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; A Fothergill; M Ghannoum; E Manavathu; L Ostrosky-Zeichner; M Pfaller; M Rinaldi; W Schell; T Walsh
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Authors:  P Connolly; L J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.

Authors:  S Kohler; L J Wheat; P Connolly; C Schnizlein-Bick; M Durkin; M Smedema; J Goldberg; E Brizendine
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Treatment of histoplasmosis with MK-991 (L-743,872).

Authors:  J R Graybill; L K Najvar; E M Montalbo; F J Barchiesi; M F Luther; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

7.  Expression and interstrain variability of the YPS3 gene of Histoplasma capsulatum.

Authors:  Megan L Bohse; Jon P Woods
Journal:  Eukaryot Cell       Date:  2007-03-02

Review 8.  Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.

Authors:  N H Georgopapadakou
Journal:  Expert Opin Investig Drugs       Date:  2001-02       Impact factor: 6.206

9.  RNA interference in Histoplasma capsulatum demonstrates a role for alpha-(1,3)-glucan in virulence.

Authors:  Chad A Rappleye; Jacquelyn T Engle; William E Goldman
Journal:  Mol Microbiol       Date:  2004-07       Impact factor: 3.501

10.  In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Authors:  Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  6 in total

1.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

2.  Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans.

Authors:  Ahmed Khalil; Jessica A Edwards; Chad A Rappleye; Werner Tjarks
Journal:  Bioorg Med Chem       Date:  2014-12-10       Impact factor: 3.641

3.  Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.

Authors:  Jessica A Edwards; Megan M Kemski; Chad A Rappleye
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

4.  Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans.

Authors:  Keisuke Ishita; Stavros Stefanopoulos; Ahmed Khalil; Xiaolin Cheng; Werner Tjarks; Chad A Rappleye
Journal:  Bioorg Med Chem       Date:  2018-02-02       Impact factor: 3.641

5.  Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts.

Authors:  Kristie D Goughenour; Joan-Miquel Balada-Llasat; Chad A Rappleye
Journal:  J Clin Microbiol       Date:  2015-08-05       Impact factor: 5.948

Review 6.  Treatment and Prevention of Histoplasmosis in Adults Living with HIV.

Authors:  David S McKinsey
Journal:  J Fungi (Basel)       Date:  2021-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.